DE60033646D1 - Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit - Google Patents

Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Info

Publication number
DE60033646D1
DE60033646D1 DE60033646T DE60033646T DE60033646D1 DE 60033646 D1 DE60033646 D1 DE 60033646D1 DE 60033646 T DE60033646 T DE 60033646T DE 60033646 T DE60033646 T DE 60033646T DE 60033646 D1 DE60033646 D1 DE 60033646D1
Authority
DE
Germany
Prior art keywords
activity
level
subject
disease
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60033646T
Other languages
English (en)
Other versions
DE60033646T2 (de
Inventor
Roger Nitsch
Christoph Hock
Uwe Otten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec OAI AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99108722A external-priority patent/EP1050757A1/de
Application filed by Evotec OAI AG filed Critical Evotec OAI AG
Publication of DE60033646D1 publication Critical patent/DE60033646D1/de
Application granted granted Critical
Publication of DE60033646T2 publication Critical patent/DE60033646T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60033646T 1999-05-03 2000-05-02 Methoden zur diagnostizierung oder zur behandlung der alzheimer krankheit Expired - Fee Related DE60033646T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99108722A EP1050757A1 (de) 1999-05-03 1999-05-03 Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Nervenwachstumsfaktor (NGF)-Spiegel basiert sind
EP99108722 1999-05-03
EP99120211 1999-10-09
EP99120211 1999-10-09
PCT/EP2000/003913 WO2000067033A1 (en) 1999-05-03 2000-05-02 Methods of diagnosing or treating alzheimer's disease

Publications (2)

Publication Number Publication Date
DE60033646D1 true DE60033646D1 (de) 2007-04-12
DE60033646T2 DE60033646T2 (de) 2007-11-29

Family

ID=26152988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033646T Expired - Fee Related DE60033646T2 (de) 1999-05-03 2000-05-02 Methoden zur diagnostizierung oder zur behandlung der alzheimer krankheit

Country Status (6)

Country Link
US (1) US20050130233A1 (de)
EP (1) EP1173769B1 (de)
AT (1) ATE355527T1 (de)
AU (1) AU4753900A (de)
DE (1) DE60033646T2 (de)
WO (1) WO2000067033A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271568A1 (en) * 2002-09-02 2004-03-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
WO2004032868A2 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
JP2007151680A (ja) * 2005-12-01 2007-06-21 Hi-Lex Corporation スカフォールド材料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243281B (it) * 1990-06-12 1994-05-26 Fidia Spa Metodo per la determinazione quantitativa e qualitativa di polipeptidiin liquidi proteici
WO1994019461A1 (en) * 1993-02-17 1994-09-01 Cephalon, Inc. METHOD FOR IDENTIFYING COMPOUNDS THAT INDUCE AN INCREASED LEVEL OF THE NERVE GROWTH FACTOR mRNA

Also Published As

Publication number Publication date
ATE355527T1 (de) 2006-03-15
EP1173769A1 (de) 2002-01-23
EP1173769B1 (de) 2007-02-28
WO2000067033A1 (en) 2000-11-09
AU4753900A (en) 2000-11-17
US20050130233A1 (en) 2005-06-16
DE60033646T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
DE60025526D1 (de) Elisa für vegf
ATE502119T1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
ATE283487T1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE286253T1 (de) Methoden zur diagnose oder prognose der alzheimerschen krankheit
ATE546547T1 (de) Diagnose der chronischen abstossung
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
ATE343793T1 (de) Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit.
ATE401576T1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen
ATE410521T1 (de) Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
FI951778A (fi) Menetelmä allergian toteamiseksi
RU2188429C2 (ru) Способ прогнозирования обострений вирусных гепатитов
CA2343713A1 (en) Use of pex in the treatment of metabolic bone diseases

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: EVOTEC NEUROSCIENCES GMBH, 22525 HAMBURG, DE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee